All lobbying filings

THE MCMANUS GROUP

Lobbying for ARDELYX · BioPharma Company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $60,000.00 income · posted Jan 20, 2026

Official filing document

Bills named in this filing 1

HR 6214
Kidney Care Access Protection Act

Lobbying activity 1

Medicare/Medicaid

Issues related to the 2025 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Final Rule (CMS-105-F), specifically the inclusion of oral-only drugs in the ESRD PPS Bundled Payment. H.R.6214 - Kidney Care Access Protection Act Issues related to Most Favored Nation Drug Pricing Reform

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.